FDA warns about Actos link to bladder cancer, but no US ban yet
This article was originally published in Scrip
Executive Summary
US regulators were not as eager as French and German officials to ban the use of Takeda Pharmaceuticals' Type II diabetes drug Actos (pioglitazone) after it had been linked to bladder cancer, with the US FDA determining for now that the medicine's labeling only needs to be updated with new warnings.